Skip to Main Content
Advertisement
Close
About the Press
Our Philosophy
Our Staff
Our History
About the University
Contact Us
Advertise
For Librarians
Rights & Permissions
Permissions & Licensing
Terms of Use
Copyright Agent
Publication Fees
License to Publish: Gold OA
License to Publish: Green OA
Privacy Policy
Books
JCB
Journal of Cell Biology
JEM
Journal of Experimental Medicine
JGP
Journal of General Physiology
LSA
Life Science Alliance
JCB
JEM
JGP
LSA
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Journal of Experimental Medicine
Search
Advanced Search
User Tools Dropdown
Register
Sign In
Toggle Menu
Menu
Articles
Newest Articles
Current Issue
Browse Archive
Browse by Topic
Reviews & Opinion
Editorials
Found in Translation
Insights
People & Ideas
Perspectives
Reviews
Viewpoint
Collections
CME Articles
Special Collections
Special Focus
Email Alerts
About
History
Editors & Staff
Journal Metrics
Policies & Permissions
Advertise
Contact Us
Privacy Policy
Submit
Submit
Instructions for Authors
Publication Fees
Read & Publish Author Guide
Author Services
Skip Nav Destination
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor
J Exp Med
(2011) 208 (5): 973–986.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to
our privacy policy.
Accept
